Boothbay Fund Management LLC Has $2.42 Million Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Boothbay Fund Management LLC grew its stake in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 105.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 351,527 shares of the company's stock after acquiring an additional 180,372 shares during the period. Boothbay Fund Management LLC owned about 1.17% of Silence Therapeutics worth $2,419,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics in the fourth quarter valued at $26,000. GAMMA Investing LLC raised its position in Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company's stock valued at $42,000 after buying an additional 5,233 shares during the period. Barclays PLC raised its position in Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock valued at $42,000 after buying an additional 2,793 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Silence Therapeutics in the 4th quarter worth about $69,000. Finally, Virtus ETF Advisers LLC boosted its position in Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock worth $74,000 after acquiring an additional 6,098 shares during the period. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Stock Performance

Shares of Silence Therapeutics stock traded up $0.31 during midday trading on Thursday, reaching $4.01. 237,984 shares of the company's stock traded hands, compared to its average volume of 295,289. Silence Therapeutics plc has a 52 week low of $1.97 and a 52 week high of $24.38. The company's 50 day simple moving average is $3.50 and its 200 day simple moving average is $7.27. The company has a market cap of $120.02 million, a price-to-earnings ratio of -2.55 and a beta of 1.25.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research report on Friday, March 7th. Morgan Stanley cut their target price on shares of Silence Therapeutics from $49.00 to $45.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. BMO Capital Markets lowered their price target on shares of Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group dropped their price target on shares of Silence Therapeutics from $6.00 to $4.00 and set a "sell" rating on the stock in a research note on Tuesday, March 4th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.67.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.